Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Dermatology
•
Systemic autoimmune diseases
Do you see a role for early, aggressive treatment for MCTD to prevent progression of disease, even though there has not been end-organ manifestations?
Related Questions
Do you always biopsy patients who present with classic skin findings of dermatomyositis?
How do you counsel patients with dermatomyositis on sun protection?
What treatments have you found most effective for cholestatic pruritus?
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?
Have you utilized JAK inhibitors in patients on dialysis?
